Form 6-K NERVGEN PHARMA CORP. For: Aug 13

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916517.html

Form 6-K NERVGEN PHARMA CORP. For: Aug 13

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916517.html

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 13 Aug 2026 07:30:00 -0400

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.
Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.
C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.
Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts.

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 13 Aug 2026 07:30:00 -0400

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.
Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.
C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.
Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts.

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 13 Aug 2026 07:30:00 -0400

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.
Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.
C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.
Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts.

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 13 Aug 2026 07:30:00 -0400

Site activation and screening for the Phase 3 RESTORE study is expected to begin in September 2026, with the first participant anticipated to be dosed shortly thereafter.
Strengthened leadership team, appointing Keith Vendola, MD, MBA as Chief Financial Officer and Marissa Volpe as SVP, Clinical Development.
C$86.8 million (US$61.1 million) in cash and cash equivalents as of June 30, 2026, which is expected to fund operations through anticipated topline data readout from RESTORE in 1H 2028.
Company plans to host inaugural R&D Day in Fall 2026, bringing together members of NervGen’s management team and leading SCI experts.

NervGen Pharma Corp (NGEN) PT Lowered to $15 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:50 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on NervGen Pharma Corp (NASDAQ: NGEN) to $15.00 (from $18.00) while maintaining a Buy rating.

The analyst commented: "We remind investors that NervGen is slated to start patient enrollment near-term in the pivotal RESTORE program of its lead asset NVG-291. In our view, the first patient could be enrolled later this summer. As a reminder, the pivotal RESTORE Phase 3 study is a randomized, double-blind, placebo-controlled trial designed to enroll ~150 adults (18–75) featuring chronic tetraplegia, focused on evaluating efficacy over a 12-week period followed

NervGen Pharma Corp (NGEN) PT Lowered to $15 at H.C. Wainwright

Tue, 14 Jul 2026 06:55:50 -0400

(Updated - July 14, 2026 6:55 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on NervGen Pharma Corp (NASDAQ: NGEN) to $15.00 (from $18.00) while maintaining a Buy rating.

Leerink Starts NervGen Pharma Corp (NGEN) at Outperform

Mon, 13 Jul 2026 06:04:14 -0400

Leerink initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Outperform rating and a price target of $10.00.

For an analyst ratings summary and ratings history on NervGen Pharma Corp click here. For more ratings news on NervGen Pharma Corp click here.

Shares of NervGen Pharma Corp closed at $1.88 yesterday.

Form 6-K NERVGEN PHARMA CORP. For: Jul 02

Thu, 02 Jul 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260702/26729578.html

Form 6-K NERVGEN PHARMA CORP. For: Jul 02

Thu, 02 Jul 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260702/26729578.html

Form SUPPL NERVGEN PHARMA CORP.

Thu, 02 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260702/26729549.html

Form SUPPL NERVGEN PHARMA CORP.

Thu, 02 Jul 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260702/26729549.html

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Thu, 11 Jun 2026 05:32:57 -0400

(Updated - June 11, 2026 5:32 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Buy rating.

The analyst comments "NervGen is advancing candidates for the treatment of neurotraumatic and neurologic conditions. Lead asset NVG-291 is set to begin a Ph. III trial in mid-2026 for chronic incomplete tetraplegia, after demonstrated encouraging efficacy in Ph. I/II study. Enrollment is slated to complete mid-2027 with data in early '28. We see our $1.1B peak estimate as achievable given favorable KOL commentary. Buy."

For an analyst ratings summary and ratings history on NervGen Pharma Corp click

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Thu, 11 Jun 2026 05:32:57 -0400

(Updated - June 11, 2026 5:32 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Buy rating.

For an analyst ratings summary and ratings history on NervGen Pharma Corp click

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Thu, 11 Jun 2026 05:32:57 -0400

(Updated - June 11, 2026 5:32 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Buy rating.

For an analyst ratings summary and ratings history on NervGen Pharma Corp click

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Thu, 11 Jun 2026 05:32:57 -0400

(Updated - June 11, 2026 5:32 AM EDT)

TD Cowen analyst Joseph Thome initiates coverage on NervGen Pharma Corp (NASDAQ: NGEN) with a Buy rating.

For an analyst ratings summary and ratings history on NervGen Pharma Corp click

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Mon, 01 Jun 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260601/26585204.html

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Mon, 01 Jun 2026 17:29:00 -0400

si-local-file:///var/storage/secattach/20260601/26585204.html

Form EFFECT NERVGEN PHARMA CORP.

Wed, 27 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260527/26552941.html

Form EFFECT NERVGEN PHARMA CORP.

Wed, 27 May 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260527/26552941.html

Form 6-K NERVGEN PHARMA CORP. For: May 26

Tue, 26 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260526/26550660.html

Form 6-K NERVGEN PHARMA CORP. For: May 26

Tue, 26 May 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260526/26550660.html

Form SUPPL NERVGEN PHARMA CORP.

Tue, 26 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260526/26550590.html

Form SUPPL NERVGEN PHARMA CORP.

Tue, 26 May 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260526/26550590.html

StreetInsider.com News Articles

Form 6-K NERVGEN PHARMA CORP. For: Aug 13

Form 6-K NERVGEN PHARMA CORP. For: Aug 13

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

NervGen Pharma Corp (NGEN) PT Lowered to $15 at H.C. Wainwright

NervGen Pharma Corp (NGEN) PT Lowered to $15 at H.C. Wainwright

Leerink Starts NervGen Pharma Corp (NGEN) at Outperform

Form 6-K NERVGEN PHARMA CORP. For: Jul 02

Form 6-K NERVGEN PHARMA CORP. For: Jul 02

Form SUPPL NERVGEN PHARMA CORP.

Form SUPPL NERVGEN PHARMA CORP.

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

TD Cowen Starts NervGen Pharma Corp (NGEN) at Buy, 'A New Generation In Spinal Cord Injury Treatment Is Here'

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Form 6-K NERVGEN PHARMA CORP. For: Jun 01

Form EFFECT NERVGEN PHARMA CORP.

Form EFFECT NERVGEN PHARMA CORP.

Form 6-K NERVGEN PHARMA CORP. For: May 26

Form 6-K NERVGEN PHARMA CORP. For: May 26

Form SUPPL NERVGEN PHARMA CORP.

Form SUPPL NERVGEN PHARMA CORP.